Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
| content:anakinra [2020/02/14 17:51] – icna | content:anakinra [2022/04/30 11:31] (current) – administrator@icnapedia.org | ||
|---|---|---|---|
| Line 2: | Line 2: | ||
| Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra). It competitively inhibits binding of IL-1α and IL-1β to the IL-1 receptor type 1. Given daily as subcutaneous injection, it has modest but significant anti-inflammatory efficacy in Rheumatoid arthritis and has been proven of particular benefit in autoinflammatory syndromes, where IL-1 seems to play a pivotal role. | Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra). It competitively inhibits binding of IL-1α and IL-1β to the IL-1 receptor type 1. Given daily as subcutaneous injection, it has modest but significant anti-inflammatory efficacy in Rheumatoid arthritis and has been proven of particular benefit in autoinflammatory syndromes, where IL-1 seems to play a pivotal role. | ||
| - | Anakinra has been reported to be useful in refractory seizures in the chronic phase of [[FIRES]][(: | + | Anakinra has been reported to be useful in refractory seizures in the chronic phase of [[FIRES]][(: |
| ===== References ===== | ===== References ===== | ||
| ~~REFNOTES~~ | ~~REFNOTES~~ | ||